ATE465412T1 - Immunsorbens-bluttests zur beurteilung von paroxysmalen zerebralentladungen - Google Patents

Immunsorbens-bluttests zur beurteilung von paroxysmalen zerebralentladungen

Info

Publication number
ATE465412T1
ATE465412T1 AT04818645T AT04818645T ATE465412T1 AT E465412 T1 ATE465412 T1 AT E465412T1 AT 04818645 T AT04818645 T AT 04818645T AT 04818645 T AT04818645 T AT 04818645T AT E465412 T1 ATE465412 T1 AT E465412T1
Authority
AT
Austria
Prior art keywords
epilepsy
immunosorb
assessing
blood tests
paroxysmal cerebral
Prior art date
Application number
AT04818645T
Other languages
English (en)
Inventor
Svetlana Dambinova
Galina Izykenova
Original Assignee
Grace Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grace Lab Inc filed Critical Grace Lab Inc
Application granted granted Critical
Publication of ATE465412T1 publication Critical patent/ATE465412T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
AT04818645T 2003-11-06 2004-11-08 Immunsorbens-bluttests zur beurteilung von paroxysmalen zerebralentladungen ATE465412T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51767103P 2003-11-06 2003-11-06
PCT/US2004/037088 WO2005046442A2 (en) 2003-11-06 2004-11-08 Immunosorbent tests for assessing paroxysmal cerebral discharges

Publications (1)

Publication Number Publication Date
ATE465412T1 true ATE465412T1 (de) 2010-05-15

Family

ID=34590180

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04818645T ATE465412T1 (de) 2003-11-06 2004-11-08 Immunsorbens-bluttests zur beurteilung von paroxysmalen zerebralentladungen

Country Status (10)

Country Link
US (1) US7820398B2 (de)
EP (1) EP1689288B1 (de)
JP (1) JP4838140B2 (de)
CN (1) CN1954211A (de)
AT (1) ATE465412T1 (de)
AU (1) AU2004288717A1 (de)
CA (1) CA2585876A1 (de)
DE (1) DE602004026767D1 (de)
EA (1) EA200600920A1 (de)
WO (1) WO2005046442A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6896872B2 (en) * 2001-06-27 2005-05-24 Svetlana A. Dambinova Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke
US20060257943A1 (en) * 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
CN101268370A (zh) * 2005-06-13 2008-09-17 Cis生物科技公司 基于nr2肽诊断和治疗脑血管事件的方法
US8536115B2 (en) 2006-08-31 2013-09-17 Centre For Addiction And Mental Health Compositions and methods for modulating AMPA receptor-mediated excitotoxicity
WO2013102264A1 (en) * 2012-01-04 2013-07-11 Centre For Addiction And Mental Health Compositions and methods for modulating ampa receptor-mediated excitotoxicity
US10610861B2 (en) 2012-12-17 2020-04-07 Accellix Ltd. Systems, compositions and methods for detecting a biological condition
US9759722B2 (en) * 2012-12-17 2017-09-12 Leukodx Ltd. Systems and methods for determining a chemical state
JP6349327B2 (ja) 2012-12-17 2018-06-27 レウコドゥックス，リミテッド 化学的状態を判定するためのシステムおよび方法
EP2863231A1 (de) * 2013-10-17 2015-04-22 Institut D'Investigaciones Biomédiques August Pi i Sunyer Diagnostisches Verfahren zum Nachweis einer GABA(A)-verwandten Autoimmunerkrankung und zugehörige Subjektmaterie
US9958521B2 (en) 2015-07-07 2018-05-01 Q Bio, Inc. Field-invariant quantitative magnetic-resonance signatures
US10194829B2 (en) 2015-07-07 2019-02-05 Q Bio, Inc. Fast scanning based on magnetic resonance history
US9665734B2 (en) 2015-09-12 2017-05-30 Q Bio, Inc. Uniform-frequency records with obscured context
US10964412B2 (en) 2015-10-20 2021-03-30 Q Bio, Inc. Population-based medical rules via anonymous sharing
US10222441B2 (en) 2016-04-03 2019-03-05 Q Bio, Inc. Tensor field mapping
US10359486B2 (en) 2016-04-03 2019-07-23 Q Bio, Inc. Rapid determination of a relaxation time
WO2018144044A1 (en) * 2017-02-03 2018-08-09 Q Bio, Inc. lTERATIVE MEDICAL TESTING OF BIOLOGICAL SAMPLES
US11650195B2 (en) 2017-02-03 2023-05-16 Q Bio, Inc. Iterative medical testing of biological samples
US10936180B2 (en) 2017-03-16 2021-03-02 Q Bio, Inc. User interface for medical information
US11360166B2 (en) 2019-02-15 2022-06-14 Q Bio, Inc Tensor field mapping with magnetostatic constraint
US11354586B2 (en) 2019-02-15 2022-06-07 Q Bio, Inc. Model parameter determination using a predictive model
CN113631924A (zh) 2019-05-24 2021-11-09 富士瑞必欧株式会社 甲状腺球蛋白的测定方法和测定试剂
US12320880B2 (en) 2019-09-27 2025-06-03 Q Bio, Inc. Maxwell parallel imaging
US11614509B2 (en) 2019-09-27 2023-03-28 Q Bio, Inc. Maxwell parallel imaging
EP4036111A4 (de) 2019-09-27 2023-10-25 Fujirebio Inc. Immunoassay für hepatitis-b-virus-kern-antigen und kit dafür
WO2021062154A1 (en) 2019-09-27 2021-04-01 Q Bio, Inc. Maxwell parallel imaging
US20230160912A1 (en) 2020-03-31 2023-05-25 Fujirebio Inc. Method for immunoassay of amyloid beta in blood, and kit for same
CN117616277A (zh) 2021-08-06 2024-02-27 株式会社先端生命科学研究所 甲状腺球蛋白的免疫检测及用于其的试剂盒
US11614508B1 (en) 2021-10-25 2023-03-28 Q Bio, Inc. Sparse representation of measurements

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879289A (en) * 1988-05-24 1989-11-07 Marion Laboratories, Inc. Method of ameliorating epileptic seizures
WO1991006648A1 (en) * 1989-10-27 1991-05-16 The Salk Institute For Biological Studies Glutamate receptor compositions and methods
WO1993000586A1 (fr) 1991-06-26 1993-01-07 Obschestvo S Ogranichennoi Otvetstvennostju 'dies' Immunoadsorbant utilise dans le diagnostic de l'epilepsie et d'un groupe a risque
WO1994006345A2 (en) 1992-09-11 1994-03-31 Dambinova Svetlana Alexandrovn Immunosorbent for use in the diagnosis of neuro-psychological disorders, and use thereof
RU2112243C1 (ru) 1995-11-29 1998-05-27 Светлана Александровна Дамбинова Набор "па-тест" для диагностики неврологических заболеваний
US6896872B2 (en) * 2001-06-27 2005-05-24 Svetlana A. Dambinova Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke
US20050233390A1 (en) * 2003-04-09 2005-10-20 Allen John W Device including a proteinaceous factor, a recombinant proteinaceous factor, and a nucleotide sequence encoding the proteinaceous factor
US20060257943A1 (en) * 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery

Also Published As

Publication number Publication date
CN1954211A (zh) 2007-04-25
JP2007517188A (ja) 2007-06-28
EP1689288B1 (de) 2010-04-21
US7820398B2 (en) 2010-10-26
WO2005046442A2 (en) 2005-05-26
AU2004288717A2 (en) 2005-05-26
EA200600920A1 (ru) 2007-04-27
EP1689288A2 (de) 2006-08-16
EP1689288A4 (de) 2007-09-26
DE602004026767D1 (de) 2010-06-02
JP4838140B2 (ja) 2011-12-14
WO2005046442A3 (en) 2006-12-07
AU2004288717A1 (en) 2005-05-26
CA2585876A1 (en) 2005-05-26
US20050181466A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
ATE465412T1 (de) Immunsorbens-bluttests zur beurteilung von paroxysmalen zerebralentladungen
Galvez-Sánchez et al. Depression and trait-anxiety mediate the influence of clinical pain on health-related quality of life in fibromyalgia
Sun et al. Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV
Gallagher et al. Ageing: the cholinergic hypothesis of cognitive decline
Sammler et al. Prosody meets syntax: the role of the corpus callosum
Chen et al. Treadmill exercise suppressed stress-induced dendritic spine elimination in mouse barrel cortex and improved working memory via BDNF/TrkB pathway
Bruehl et al. The relationship between pain sensitivity and blood pressure in normotensives
Prestes et al. Temporal processing and long-latency auditory evoked potential in stutterers
van den Bos et al. Pathophysiological associations of transcallosal dysfunction in ALS
Ferreira‐Junior et al. Exercise training increases GAD65 expression, restores the depressed GABAA receptor function within the PVN and reduces sympathetic modulation in hypertension
Ris et al. Sexual dimorphisms in the effect of low‐level p25 expression on synaptic plasticity and memory
da Silva et al. Localized APP expression results in progressive network dysfunction by disorganizing spike timing
GB0403490D0 (en) Screening methods
Alanazy et al. Decremental responses in patients with motor neuron disease
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
Gainotti Measures of cognitive and emotional changes in multiple sclerosis and underlying models of brain dysfunction
Kavcic et al. The relationship between baseline EEG spectra power and memory performance in older African Americans endorsing cognitive concerns in a community setting
Gupta et al. Effect of Antiepileptic drugs on Psychomotor Functions and Memory in Epilepsy Patients.
Safi et al. Recruitment of the left precentral gyrus in reading epilepsy: a multimodal neuroimaging study
Jarkiewicz et al. Can new paradigms bring new perspectives for mismatch negativity studies in schizophrenia?
De Las Heras et al. Lesion location changes the association between brain excitability and motor skill acquisition post-stroke
Colzato et al. Retraction note to: the effect of gamma-enhancing binaural beats on the control of feature bindings
Yamamoto et al. Characteristic features of electroencephalogram in a pediatric patient with grin1 encephalopathy
Reinhart et al. Assessing neglect dyslexia with compound words.
Šulcová et al. Evaluation of GABAAR-mediated inhibition in the human brain using TMS-evoked potentials

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties